Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

519
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
519
Hazard Ratio01:12

Hazard Ratio

686
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
686
Decision Making: P-value Method01:09

Decision Making: P-value Method

7.1K
The process of hypothesis testing based on the P-value method includes calculating the P- value using the sample data and interpreting it.
First, a specific claim about the population parameter is proposed. The claim is based on the research question and is stated in a simple form. Further, an opposing statement to the claim  is also stated. These statements can act as null and alternative hypotheses:  a null hypothesis would be a neutral statement while the alternative hypothesis can...
7.1K
Decision Making: Traditional Method01:14

Decision Making: Traditional Method

5.7K
The process of hypothesis testing based on the traditional method includes calculating the critical value, testing the value of the test statistic using the sample data, and interpreting these values.
First, a specific claim about the population parameter is decided based on the research question and is stated in a simple form. Further, an opposing statement to this claim is also stated. These statements can act as null and alternative hypotheses, out of which a null hypothesis would be a...
5.7K
Decision Making01:20

Decision Making

1.2K
Decision-making is a fundamental cognitive process that involves evaluating alternatives and selecting among them. This process can range from simple choices, such as deciding what to wear, to complex decisions, like choosing a major in college or a career path. The complexity of the decision often dictates the approach we use, which can be broadly categorized into two types: automatic and controlled decision-making.
Automatic decision-making is fast, intuitive, and relies on gut feelings...
1.2K
Odds Ratio01:09

Odds Ratio

2.1K
The odds ratio (OR) is a statistical measure used extensively in epidemiology and research to quantify the strength of association between exposure and outcome across different groups. Unlike relative risk, which compares the probabilities of an event occurring, the odds ratio compares the odds of an event occurring in the exposed group to the odds of it occurring in the unexposed group. The odds, in this context, are calculated as the probability of the event happening divided by the...
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Expediting treatments in the 21st century: orphan drugs and accelerated approvals.

Orphanet journal of rare diseases·2024
Same author

MIT CAACB Risk Assessment Case Study: Assessing Virus Cross-Contamination Risk between Two Simultaneous Processes in an Open Biomanufacturing Facility.

PDA journal of pharmaceutical science and technology·2022
Same author

Using a Benefit-Risk Analysis Approach to Capture Regulatory Decision Making: Renal Cell Carcinoma.

Clinical pharmacology and therapeutics·2019
Same author

Using a Benefit-Risk Analysis Approach to Capture Regulatory Decision Making: Melanoma.

Clinical pharmacology and therapeutics·2019
Same author

A Benefit-Risk Analysis Approach to Capture Regulatory Decision-Making: Multiple Myeloma.

Clinical pharmacology and therapeutics·2017
Same author

A Benefit-Risk Analysis Approach to Capture Regulatory Decision-Making: Non-Small Cell Lung Cancer.

Clinical pharmacology and therapeutics·2016

Related Experiment Video

Updated: Mar 15, 2026

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents
07:05

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents

Published on: September 10, 2018

6.5K

Benefit-Risk Analysis for Decision-Making: An Approach.

G K Raju1,2, K Gurumurthi1, R Domike1

  • 1Light Pharma, Inc., Cambridge, Massachusetts, USA.

Clinical Pharmacology and Therapeutics
|September 15, 2016
PubMed
Summary
This summary is machine-generated.

This study presents an enhanced benefit-risk analysis approach for drug lifecycle decisions. It integrates qualitative methods with international standards for explicit, comparable assessments, aiding regulatory choices.

More Related Videos

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.7K
Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods
13:04

Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods

Published on: September 19, 2012

12.5K

Related Experiment Videos

Last Updated: Mar 15, 2026

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents
07:05

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents

Published on: September 10, 2018

6.5K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.7K
Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods
13:04

Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods

Published on: September 19, 2012

12.5K

Area of Science:

  • Pharmacoeconomics and Health Policy
  • Drug Regulatory Science
  • Clinical Decision-Making

Background:

  • Benefit-risk analysis is crucial for drug lifecycle decision-making.
  • Existing qualitative approaches, like the US Food and Drug Administration (FDA) method, can be enhanced for greater explicitness and comparability.
  • A lifecycle perspective is essential for comprehensive drug evaluation.

Purpose of the Study:

  • To explore and propose an enhanced benefit-risk analysis approach.
  • To support robust decision-making throughout a drug's lifecycle.
  • To enable explicit aggregation and comparison of benefits and risks on a common basis.

Main Methods:

  • Developed an approach building on the qualitative FDA framework.
  • Incorporated international standards and guidance for quantitative comparison.
  • Applied the approach to six lifecycle decisions across two case studies.

Main Results:

  • Demonstrated the application of the enhanced approach on real-world drug lifecycle decisions.
  • Case studies included natalizumab for multiple sclerosis (MS) and bedaquiline for multidrug-resistant tuberculosis (MDR-TB).
  • The approach facilitated explicit analysis and comparison of benefits and risks.

Conclusions:

  • The proposed benefit-risk analysis approach offers a more explicit and comparable method for decision-making.
  • This enhanced approach supports informed decisions across the drug lifecycle, from approval to withdrawal.
  • It provides a valuable tool for regulatory bodies and pharmaceutical companies.